Tanimilast is a novel inhaled PDE4 inhibitor currently undergoing phase III clinical development for COPD which shows promising pharmacodynamic results associated with a good tolerability and safety profile (14, 24). Here, PDE4A is linked to chronic obstructive pulmonary disease.